Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens

American Journal of Kidney Diseases

Volumn 38, Issue 2, 2001, Pages 256-264

  Mok, Chi Chiu ^a,b   Kwan Ho, Carmen Tsz ^a,b   Siu, Yui Pong ^a,b   Chan, Kwok Wah ^a,b   Kwan, Tsz Hoi ^a,b   Lau, Chak Sing ^a,b   Wong, Raymond W S ^a,b   Au, Tak Cheung ^a,b  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Azathioprine (AZA); Cytotoxic; Immunosuppressive therapy; Outcome; Renal; Systemic lupus erythematosus (SLE)

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; SERUM ALBUMIN;

ADULT; ALOPECIA; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MENSTRUATION DISORDER; NAUSEA; PROTEINURIA; REMISSION; SEROLOGY; TREATMENT FAILURE;

EID: 0034910925     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.26084     Document Type: Article

References (42)

1. Prognostic determinants in lupus nephritis: A long term clinicopathological study
2. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus
3. A comparison of the quality of life of patients with systemic lupus erythematosus with and without end-stage renal disease
4. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization
5. Clinical usefulness of the morphological classification of lupus nephritis
6. Lupus nephritis in southern Chinese patients: Clinicopathological findings and long-term outcome
7. The course and treatment of lupus nephritis
8. Lupus nephritis in children - A review of 167 patients
9. The prognosis of lupus nephritis in African-Americans: A retrospective analysis
10. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
11. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
12. The 1982 revised criteria for the classification of systemic lupus erythematosus
13. Prognostic factors in lupus nephritis. Contribution of renal histologic data
14. Role of pathology indices in the management of severe lupus glomerulonephritis
15. Outcome criteria for lupus nephritis trials: A critical overview
16. Controlled trial of pulse methylprednisolone versus two regimens of pulse CYC in severe lupus nephritis
17. Prednisone and azathioprine compared to prednisone plus low dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis
18. Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide
19. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
20. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
21. Treatment of lupus nephritis: A meta-analysis of clinical trials
22. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis
23. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis
24. NIH conference. Lupus nephritis
25. Intermittent intravenous cyclophosphamide therapy for lupus nephritis
26. Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis
27. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis
28. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: A prospective five-year study
29. Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations
30. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis
31. Treatment of lupus glomerulonephritis with intravenous cyclophosphamide
32. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus
33. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis
34. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network
35. Immunosuppressive therapy in lupus nephritis
36. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus
37. Outcome of 85 lupus nephritis patients treated with intravenous cyclophosphamide: A single centre 10 year experience
38. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide
39. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study
40. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide treatment
41. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus
42. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy